Milestone Pharmaceuticals In (MIST) 13F Positioning & Ownership Changes (Q2 2026)

MIST ranks #5127 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

MIST is a disclosed holding of Steve Cohen (Point72 Asset Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

MIST is a top-conviction position for Lion Point Capital, LP — at 5.3% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in MIST belongs to Pavaki Capital Management LLC, but the position matters far more to Lion Point Capital, LP, who has 5.3% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

MIST is down 1% today, but institutions show net buying of $16.6M this quarter — a divergence between today's price move and the underlying institutional flow.

MIST reported a net loss of $84.0M over the trailing twelve months.

• Not yet profitable — net loss of $84.0M over the trailing twelve months
• Net income declined year over year, from -$55.5M to -$84.0M
• Operating cash flow was negative, using $49.0M in cash
• Current ratio of 8.01x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.72x equity — within a conventional range